This is a severe type of anemia that doesn't get better with standard treatments. It's often a type of megaloblastic anemia.
Every report comes from a Lived member, sent anonymously.
Have you had Blood Transfusion for Refractory Anemia?
Refractory anemia is anemia that does not get better with the usual treatment. Anemia means the blood carries too little hemoglobin, the protein in red blood cells that delivers oxygen, so the body's tissues get less oxygen than they need. People often feel tired or weak, become short of breath with ordinary activity and look paler than usual. A milder case may cause no symptoms and be found on a routine blood test. The term is used in two ways. Doctors sometimes call any anemia refractory when it has not responded as expected, for example iron deficiency that does not improve with iron. In that sense, the word signals that the real cause has not yet been found. More specifically, refractory anemia was for decades the name of a form of myelodysplastic syndrome (MDS), a group of bone marrow cancers in which the marrow's blood-forming cells fail to mature into healthy blood cells. Newer classifications have replaced that name with MDS terms (the current World Health Organization system calls it MDS with low blasts), but the older label still appears in many records and reports. Much of this page focuses on that meaning, because it shapes how the condition is followed and treated.
When an anemia simply has not responded to treatment, the reason is usually an underlying problem that is still active or has not been identified. Celiac disease, for example, can interfere with iron absorption and sometimes shows up only as anemia that iron does not fix. A bone marrow disorder that prevents red cells from being made properly is another possibility, and it becomes more likely when other blood counts are also low. In MDS, the trouble begins in the marrow's own stem cells, which acquire gene changes that disrupt normal blood cell production. For most people, the reason those changes happen is not known. Risk rises with age, especially after 60, and after chemotherapy or radiation therapy for an earlier cancer. Exposure to certain chemicals, including tobacco smoke, benzene and some pesticides, is also linked to a higher risk. A risk factor does not mean someone will develop MDS, and many people who develop it have none.
Diagnosis starts with a complete blood count (CBC), which measures hemoglobin and counts red cells, white cells and platelets. In refractory anemia, red cells are often larger than normal. A clinician also checks common causes of anemia, such as low iron, vitamin B12 or folate, and asks whether earlier treatment was taken as prescribed and for long enough. When no ordinary cause explains the anemia, or when white cells or platelets are also low, the next step is usually a bone marrow aspiration and biopsy. After the skin is numbed, a hollow needle removes a small sample of marrow and bone, from the hip bone or, sometimes, the breastbone. A pathologist examines how the cells are maturing and counts blasts, very immature cells whose share separates lower-risk MDS from higher-risk MDS and from acute leukemia. Chromosome and gene tests on the sample look for changes such as a missing piece of chromosome 5 (called deletion 5q) or a mutation in a gene called SF3B1. These findings affect both the outlook and which treatments are most likely to work. Specialists combine the results into a risk score, such as the revised International Prognostic Scoring System (IPSS-R), to place the disease in a risk group that guides treatment.
When anemia is refractory because of an unrecognized cause, treatment focuses on finding and treating that cause rather than repeating the same therapy. For lower-risk MDS, the usual goals are to raise hemoglobin, reduce or end the need for transfusions and protect quality of life. Red blood cell transfusions relieve symptoms quickly but have to be repeated. Each transfusion also adds iron the body cannot easily remove, and over many transfusions that buildup can damage tissues and organs. People who receive many transfusions may take iron chelation medicines, which bind the extra iron so the body can clear it. Several medicines aim to make transfusions less frequent. Erythropoiesis-stimulating agents (ESAs), lab-made versions of the hormone that tells the marrow to make red cells, such as epoetin alfa (Procrit, Retacrit) or darbepoetin alfa (Aranesp), are a common first choice when the body's own level of that hormone is not already high (generally below 500 units per liter). About 4 in 10 people respond, and responses usually last around one and a half to two years. In the US, using them for MDS is off-label. Luspatercept (Reblozyl), an injection under the skin every three weeks, helps developing red cells finish maturing. It is approved for anemia in very low- to intermediate-risk MDS, either as a first treatment or, in some subtypes, after an ESA stops working. In a large trial comparing it with an ESA as a first treatment, about 59% of people on luspatercept went at least 12 weeks without a transfusion while their hemoglobin rose, compared with about 31% on the ESA. Imetelstat (Rytelo), an infusion into a vein every four weeks, blocks telomerase, an enzyme the abnormal marrow cells depend on to keep dividing. It is approved for people who need frequent transfusions (at least four units over eight weeks) when ESAs have not worked, have stopped working or are unsuitable. In its main trial, 40% went at least eight weeks without a transfusion, compared with 15% on placebo. It often lowers white cell and platelet counts for a time, so blood counts are checked closely. Lenalidomide (Revlimid), a capsule taken by mouth, works especially well when MDS carries the deletion 5q change: in a key trial, more than half of people stopped needing transfusions for at least six months. It can also lower white cell and platelet counts. Because it can cause severe birth defects, it is available only through a restricted program with pregnancy testing and contraception requirements. Other options a hematologist (blood specialist) may discuss include medicines that calm the immune system for selected people, azacitidine and decitabine, which may slow progression toward leukemia, and a stem cell transplant, which replaces the diseased marrow with donor cells. The choice depends on the risk group, age and overall health.
The course varies widely. For many people with lower-risk MDS, care becomes a long-term routine of blood counts, specialist visits and, for some, transfusions on a regular schedule. Fatigue and the time spent on appointments and transfusions are often the main daily burdens. Responses to anemia treatments often fade over time, so moving from one medicine to the next is common. Even when anemia improves, MDS can progress to a higher-risk form or to acute myeloid leukemia (AML), a fast-growing blood cancer. That is one reason blood counts, and sometimes the marrow, are rechecked over time. How likely progression is depends on the risk group, the blast count and the gene findings, so individual outlook is best discussed with the treating specialist. When refractory anemia turns out to have another cause, such as an absorption problem, the outlook depends on that cause and on how well it can be treated.
See a clinician if tiredness, shortness of breath with ordinary activity or paler skin persists, or if anemia found on a blood test has not improved with the treatment you were given. Contact your care team if you notice easy bruising or bleeding, or tiny flat red spots under the skin, which can mean platelets are low. If your white blood cell count is low, or you take a treatment that lowers it, call your care team right away for a fever of 100.5°F (38°C) or higher or for chills. Infections at these times can be life threatening and need urgent medical attention.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Refractory Anemia is like, what's helped you, or ask the community a question.